mc val cit pab

MC-VAL-CIT-PAB-VX765 or MC-VAL-CIT-PABC-VX765 is a VX765 derivative that can be conjugated to antibodies, proteins, or polymers for targeted drug delivery. MC-Val- CIT -PAB is a cathepsin cleavable ADC connector, which has been widely used in the preparat

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a conjugate of the DNA topoisomerase I inhibitor DX-8951 and a cathepsin-cleavable antibody-drug conjugate (ADC) linker, designed for targeted cancer therapy applications.

Mc-Val-Cit-PAB-Gefitinib chloride is a conjugate agent-linker for antibody-drug conjugates (ADCs) that combines Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the proprietary ADC linker Mc-Val-Cit-PAB [1].

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound featuring Auristatin E, a potent cytotoxic tubulin modifier, connected through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate designed for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected through the MC-Val-Cit-PAB ADC linker. This configuration endows it with significant antitumor activity.

MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent Eg5 inhibitor and a click chemistry reagent [1].

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to link to the potent antitumor agent dimethylDNA31. Notably, dimethylDNA31 also demonstrates significant bactericidal activity against both persister and stationary-phase Staphylococcus aureus.

MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker that combines the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, to enhance its ability to target and kill cancer cells effectively.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-NH-C2-NH-Boc is a cathepsin-cleavable ADC linker utilized in constructing antibody-drug conjugates (ADCs) [1].

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a conjugate that acts as an immune agonist targeting both HER2-TLR7 and HER2-TLR8 pathways [1].

MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for antibody-drug conjugates (ADC) that exhibits potent antitumor activity. This compound utilizes Retapamulin, a ribosome inhibitor, connected through the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB ADC linker.

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

Fmoc-Val-Cit-PAB is a linker for antibody-drug-conjugation (ADC).

Val-cit-PAB-OH is an ADC linker that is cleavable.

Mal-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Doxorubicin-MVCP (MC-Val-Cit-PAB-Doxorubicin) is a Doxorubicin derivative with an MC-Val-Cit-PAB linker.

MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

SuO-Glu-Val-Cit-PAB-MMAE is a chemical compound comprising a cleavable ADC linker, SuO-Glu-Val-Cit-PAB, and a potent tubulin inhibitor known as MMAE. It is utilized in the synthesis of antibody-drug conjugates (ADCs).

DBCO-Val-Cit-PABC-OH is a cleavable linker employed in the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Gly-Gly-Phe-Gly-PAB-OH, also known as Mc-GGFG-PAB-OH, serves as a cleavable ADC linker exclusively employed in the synthesis of antibody-drug conjugates (ADCs).

MC-VC-PAB-NH2 TFA is a cleavable linker for antibody-drug conjugates (ADCs) [1] utilized in their synthesis.

PDP-C1-Ph-Val-Cit is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker employed for synthesizing antibody-drug conjugates (ADCs)[1]. It also serves as a PEG-based PROTAC linker for the synthesis of PROTACs[2].

MC-VC-PAB-NH2 is a cleavable linker vital in ADC synthesis. MC-VC-PAB-NH2 joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

MC-Val-Ala-PAB-PNP is a cleavable ADC linker. MC-Val-Ala-PAB-PNP can be used in the synthesis of antibody-drug conjugates (ADCs).

Boc-Val-Ala-PAB-PNP is an ADC linker employed for the synthesis of antibody-drug conjugates (ADCs)[1]. This cleavable compound efficiently facilitates the attachment of drugs to antibodies, allowing for targeted delivery and release of therapeutic agents within the body, making it an important component in ADC development.

PSMA-Val-Cit-PAB-MMAE is a novel PSMA-targeted small-molecule conjugate leveraging monomethyl auristatin E (MMAE) for prostate cancer chemotherapy.

Fmoc-Val-D-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).

MAL-di-EG-Val-Cit-PAB-MMAF refers to a chemical compound that comprises the linker (MAL-di-EG-Val-Cit-PAB) and the potent blocker of tubulin polymerization (MMAF, Monomethyl auristatin F)[1].

Val-Cit-PAB-MMAE is a molecular entity designed to function as an antibody-drug conjugate (ADC) or as a component of bispecific antigen-binding molecules, specifically targeting the hepatocyte growth factor receptor known as c-Met (MET).

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1].

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Dolastatin10 (a tubulin polymerization inhibitor) connected through the MC-Sq-Cit-PAB ADC linker.

MC-vc-PAB-Tubulysin M is a conjugate composed of a cleavable ADC linker (MC-vc-PAB) and the cytotoxic tubulin inhibitor Tubulysin M, which inhibits tubulin polymerization, resulting in cell cycle arrest and apoptosis.

Val-Ala-PAB is a building block in the synthesis of Tesirine (a.k.a. SG3249), a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. Reagent in the preparation of pyrrolobenzodiazepine dimers and their antibody conjugates containing pepti

Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Compound D7, also known as Mal-PEG8-Val-Ala-PAB-SB-743921, is a drug-linker conjugate for antibody-drug conjugates (ADC). It comprises the KSP inhibitor SB-743921 connected through a linker and is utilized in the synthesis of ADCs [1].

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

Val-Cit-amide-Cbz-N(Me)-Maytansine is a molecule that functions both as an antibody and a bispecific antigen-binding entity, targeting the hepatocyte growth factor receptor c-Met (MET), and is used in the formulation of antibody-drug conjugates (ADCs) [1].

DBCO-Val-Cit-PABC-PNP is a cleavable linker for antibody-drug conjugate (ADC) synthesis[1].

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable 2-unit polyethylene glycol (PEG) based ADC linker utilized in the construction of antibody-drug conjugates (ADCs)[1].

Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide.

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

Vat-Cit-PAB-Monomethyl Dolastatin 10 is an ADC linker-conjugated drug designed to deliver potent antitumor activity. It achieves this through Monomethyl Dolastatin 10, a potent tubulin inhibitor, connected via the Vat-Cit-PAB ADC linker.